Part 11 of 49 - Video Presentations of the "1st Conference on Integrating Early Detection of Heart and Lung Disease through Low-Dose CT": Day 1 Session 2: Introduction

Thursday, September 19, 2024 | New York Academy of Medicine (NYAM)

1216 5th Ave, New York, NY 10029

Dr. Jim Mulshine, MD, introduces Session 2 by highlighting the significance of early detection in averting premature deaths from thoracic diseases. He emphasized the need to measure the effectiveness of screening programs by their ability to detect and treat stage 1 cancers, rather than just the number of screenings performed. In addition, he proposes a reimbursement model based on the effectiveness of screenings, particularly the identification and resection of stage 1 cancers within a year, to enhance screening program efficacy.

Watch Dr. Jim Mulshine's Introductory Presentation:

Dr. Jim Mulshine

Expand to Read the Text Transcript

Transcript of Dr. Jim Mulshine's Introductory Presentation:

Click Here to Watch the Video

[Jim Mulshine] [0.80s] Yes.

[Jim Mulshine] [1.04s] You know David, and, I'm Jim Mulshine.

[Jim Mulshine] [3.68s] And as we get as we assemble, we're gonna be give doing this next session, which is called averting premature death from lung disease by early detection and should be by thoracic disease by early detection.

[Jim Mulshine] [18.39s] And, this is a very important thing.

[Jim Mulshine] [22.39s] You kind of get you measure what you get, and, you get what you measure.

[Jim Mulshine] [29.79s] And, this is a issue where we we have to start sculpting what should be the goal, what should be the endpoint of screening, and premature death is perhaps the most important.

[Jim Mulshine] [43.40s] Now the reason why I say this is because we do a lot of stuff now for the good intentions, but it's not carefully defined.

[Jim Mulshine] [53.08s] An example being the reimbursement we do, HEDIS measures, star measures, whatnot, that, our good friend, Bruce Pianceen, spent a lot of time on.

[Jim Mulshine] [63.77s] And what he's pointed out with those things is we pay for the process.

[Jim Mulshine] [68.72s] So how many people got mammography?

[Jim Mulshine] [71.03s] How many people got colonoscopy?

[Jim Mulshine] [72.63s] How many people got whatever?

[Jim Mulshine] [74.31s] And what Bruce says is if you really want to get the job done, you pay for the yield.

[Jim Mulshine] [81.05s] The yield being when after you screen, how many people had potentially lethal disease detected and resected or intervened with in a positive way.

[Jim Mulshine] [93.05s] And so his yield measure would be reimbursed on the basis of stage 1 cancers identified and and resected within a year of screening.

[Jim Mulshine] [106.74s] And that yield measure will drive the entire process through to completion so that will be a much more important thing than what we do right now in terms of just looking at initial compliance.

[Jim Mulshine] [120.71s] So we're emphasizing the process.

[Jim Mulshine] [123.03s] So after that statement, I think everybody's here.

[Jim Mulshine] [125.28s] We're ready to go.

[Jim Mulshine] [126.47s] You want to

[David Yankelevitz] [129.44s] Just to say, the, cardiac session was pretty spectacular, so not to put any pressure on you guys.

[David Yankelevitz] [140.47s] So our first speaker is gonna give us a perspective on LDCT for lung cancer, Claudia.

The presentations were hosted by I-ELCAP – The International Early Lung Cancer Action Program.

View the Presentations from the Entire Conference

View the Agenda